Supernus Pharmaceuticals annual net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Supernus Pharmaceuticals Net Income Growth & History (SUPN)
Supernus Pharmaceuticals's net income was −$38.5M for fiscal 2025.
View full Supernus Pharmaceuticals company overviewSupernus Pharmaceuticals annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$38.5M | −$112.4M | — |
| 2024 | 2024-12-31 | $73.9M | $72.5M | +5512.84% |
| 2023 | 2023-12-31 | $1.3M | −$59.4M | −97.83% |
| 2022 | 2022-12-31 | $60.7M | $7.3M | +13.64% |
| 2021 | 2021-12-31 | $53.4M | −$73.5M | −57.92% |
| 2020 | 2020-12-31 | $127.0M | $13.9M | +12.29% |
| 2019 | 2019-12-31 | $113.1M | $2.1M | +1.86% |
| 2018 | 2018-12-31 | $111.0M | $53.7M | +93.76% |
| 2017 | 2017-12-31 | $57.3M | −$33.9M | −37.20% |
| 2016 | 2016-12-31 | $91.2M | $77.3M | +554.20% |
| 2015 | 2015-12-31 | $13.9M | $24.9M | — |
| 2014 | 2014-12-31 | −$10.9M | $81.3M | — |
| 2013 | 2013-12-31 | −$92.3M | −$46.0M | — |
| 2012 | 2012-12-31 | −$46.3M | −$100.1M | — |
| 2011 | 2011-12-31 | $53.8M | $92.3M | — |
| 2010 | 2010-12-31 | −$38.5M | — | — |
Supernus Pharmaceuticals quarterly net income
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$58.4M | −$80.9M | — |
| Q1 2026 | 2026-03-31 | −$2.3M | $9.5M | — |
| Q4 2025 | 2025-12-31 | −$4.1M | −$19.4M | — |
| Q3 2025 | 2025-09-30 | −$45.1M | −$83.6M | — |
| Q2 2025 | 2025-06-30 | $22.5M | $2.6M | +12.97% |
| Q1 2025 | 2025-03-31 | −$11.8M | −$12.0M | — |
| Q4 2024 | 2024-12-31 | $15.3M | $14.2M | +1204.51% |
| Q3 2024 | 2024-09-30 | $38.5M | $54.5M | — |
| Q2 2024 | 2024-06-30 | $19.9M | $20.7M | — |
| Q1 2024 | 2024-03-31 | $124,000 | −$16.8M | −99.27% |
| Q4 2023 | 2023-12-31 | $1.2M | −$24.3M | −95.39% |
| Q3 2023 | 2023-09-30 | −$16.0M | −$17.7M | — |
| Q2 2023 | 2023-06-30 | −$831,000 | −$8.7M | — |
| Q1 2023 | 2023-03-31 | $16.9M | −$8.7M | −33.84% |
| Q4 2022 | 2022-12-31 | $25.5M | $23.0M | +943.45% |
| Q3 2022 | 2022-09-30 | $1.7M | −$19.8M | −91.89% |
| Q2 2022 | 2022-06-30 | $7.9M | −$15.9M | −66.85% |
| Q1 2022 | 2022-03-31 | $25.6M | $19.9M | +349.88% |
| Q4 2021 | 2021-12-31 | $2.4M | −$28.3M | −92.06% |
| Q3 2021 | 2021-09-30 | $21.6M | −$18.4M | −46.09% |
| Q2 2021 | 2021-06-30 | $23.7M | −$10.9M | −31.56% |
| Q1 2021 | 2021-03-31 | $5.7M | −$15.8M | −73.54% |
| Q4 2020 | 2020-12-31 | $30.8M | −$2.4M | −7.13% |
| Q3 2020 | 2020-09-30 | $40.0M | $11.1M | +38.59% |
| Q2 2020 | 2020-06-30 | $34.7M | $1.9M | +5.93% |
| Q1 2020 | 2020-03-31 | $21.5M | $3.2M | +17.33% |
| Q4 2019 | 2019-12-31 | $33.1M | $7.2M | +27.95% |
| Q3 2019 | 2019-09-30 | $28.9M | $849,000 | +3.03% |
| Q2 2019 | 2019-06-30 | $32.7M | $2.0M | +6.47% |
| Q1 2019 | 2019-03-31 | $18.3M | −$8.0M | −30.40% |
| Q4 2018 | 2018-12-31 | $25.9M | $12.2M | +89.58% |
| Q3 2018 | 2018-09-30 | $28.0M | $12.1M | +75.50% |
| Q2 2018 | 2018-06-30 | $30.7M | $13.4M | +76.97% |
| Q1 2018 | 2018-03-31 | $26.4M | $16.1M | +155.92% |
| Q4 2017 | 2017-12-31 | $13.7M | −$662,000 | −4.62% |
| Q3 2017 | 2017-09-30 | $16.0M | −$45.9M | −74.18% |
| Q2 2017 | 2017-06-30 | $17.4M | $7.1M | +69.43% |
| Q1 2017 | 2017-03-31 | $10.3M | $5.5M | +113.41% |
| Q4 2016 | 2016-12-31 | $14.3M | $7.5M | +108.96% |
| Q3 2016 | 2016-09-30 | $61.8M | $57.9M | +1478.80% |
| Q2 2016 | 2016-06-30 | $10.3M | $7.8M | +320.64% |
| Q1 2016 | 2016-03-31 | $4.8M | $4.1M | +553.79% |
| Q4 2015 | 2015-12-31 | $6.9M | $3.1M | +80.96% |
| Q3 2015 | 2015-09-30 | $3.9M | $6.3M | — |
| Q2 2015 | 2015-06-30 | $2.4M | −$765,000 | −23.89% |
| Q1 2015 | 2015-03-31 | $738,000 | $16.3M | — |
| Q4 2014 | 2014-12-31 | $3.8M | $26.2M | — |
| Q3 2014 | 2014-09-30 | −$2.4M | $21.7M | — |
| Q2 2014 | 2014-06-30 | $3.2M | $30.6M | — |
| Q1 2014 | 2014-03-31 | −$15.5M | $2.9M | — |
| Q4 2013 | 2013-12-31 | −$22.4M | −$8.9M | — |
| Q3 2013 | 2013-09-30 | −$24.1M | −$10.6M | — |
| Q2 2013 | 2013-06-30 | −$27.4M | −$17.3M | — |
| Q1 2013 | 2013-03-31 | −$18.4M | −$9.1M | — |
| Q4 2012 | 2012-12-31 | −$13.5M | −$95.5M | — |
| Q3 2012 | 2012-09-30 | −$13.5M | −$3.7M | — |
| Q2 2012 | 2012-06-30 | −$10.0M | −$2.6M | — |
| Q1 2012 | 2012-03-31 | −$9.3M | $1.8M | — |
| Q4 2011 | 2011-12-31 | $82.0M | — | — |
| Q3 2011 | 2011-09-30 | −$9.7M | — | — |
| Q2 2011 | 2011-06-30 | −$7.4M | — | — |
| Q1 2011 | 2011-03-31 | −$11.0M | — | — |
Supernus Pharmaceuticals net income trends
Over the last five fiscal years, Supernus Pharmaceuticals's net income decreased from $127.0M to −$38.5M, a change of −$165.5M. The latest reported quarter, Q2 2026, shows −$58.4M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Supernus Pharmaceuticals source filings ↗Community posts
Supernus and Indivior report sales growth ahead of their expected merger closing
Supernus ($SUPN) reported third-quarter 2026 revenue of $226.8 million, up 18%, with Qelbree sales increasing 12% to $90.8 million and Onapgo contributing $17.1 million. Separately, merger partner Indivior ($INDV) posted revenue of $356 mil ...
Supernus confirms ONAPGO exclusivity and seeks a second supplier
Supernus ($SUPN) said the FDA has recognized orphan-drug exclusivity for ONAPGO, its apomorphine infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. The seven-year protection period runs from the medicine' ...
